MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
about
Novel strategies to target the ubiquitin proteasome system in multiple myelomaModification by ubiquitin-like proteins: significance in apoptosis and autophagy pathwaysDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Characterization of the ubiquitylating components of the human malaria parasite's protein degradation pathwayMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaTargeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myelomaToll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosisInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Targeting the OB-Folds of Replication Protein A with Small Moleculesp53 abnormalities and potential therapeutic targeting in multiple myeloma.Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events.Targeting p53 by small molecules in hematological malignancies.Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.Mir-509-5p joins the Mdm2/p53 feedback loop and regulates cancer cell growth.MicroRNAs: New Players in Multiple Myeloma.Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.Pharmacologic activation of p53 by small-molecule MDM2 antagonistsRestoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication.Understanding the molecular biology of myeloma and its therapeutic implications.Targeting p53-MDM2-MDMX loop for cancer therapy.The novel autophagy inhibitor elaiophylin exerts antitumor activity against multiple myeloma with mutant TP53 in part through endoplasmic reticulum stress-induced apoptosis.A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line.Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.Mechanisms of Resistance in Multiple Myeloma.Inhibition of heat shock protein response enhances PS-341-mediated glioma cell death.Nutlin's two roads toward apoptosis.Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.Stimulation of Toll-like receptor-1/2 combined with Velcade increases cytotoxicity to human multiple myeloma cells.MiRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc.Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis.Targeting p53 by small molecule p53 activators in multiple myeloma.Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop.TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.Highly efficient delivery of potent anticancer iminoquinone derivative by multilayer hydrogel cubes.
P2860
Q26773246-C405FC6E-3A5E-48C4-8BF0-19139060488FQ27011543-8680A1E6-4211-47B9-A120-2AD74BC22BA0Q27692033-FE8D1144-DB5E-42AA-B63F-C96883CEBFBBQ27974780-AB3689CD-23F5-4592-A86C-E0AFAF53B0ABQ28074490-3824182C-7076-4FEC-BE33-4EC57599028AQ28479002-DD77BCFE-580E-4CBF-8BB6-E65BAAD779EDQ28538422-850B3001-25CB-4C97-96AA-9377BC4AD313Q28542684-B0AB21CA-4B23-4179-9C96-3CAA973CCCCAQ33781249-AB5DE369-D9CD-43EC-910D-4FF4C8C8EBA1Q33852683-E13589AC-7FF4-4A70-959E-FBA3BA3BFDDAQ33865098-84246BB8-4A1C-4F42-9570-FE6AE7AA4DBBQ34636996-55A0793D-7152-445F-80B3-70CBCF94029FQ34963324-C93F0E9C-4FF5-4FC5-B696-1895F0934D08Q35552714-C804D53E-BFB6-4F25-B7CB-B07B539E414EQ35679514-58B89946-B347-41B9-AEF1-0B328A869781Q35711092-0DB03EB7-430E-4300-A2A8-B4EDA8235CD2Q36312897-4EFF7DD8-B669-4AD7-9F52-94E8F11BB781Q36731603-CAF4A6DF-A5EA-4B5F-8D9E-0509AF5C3A4AQ36862536-9616CAA6-5984-48A8-AE6C-FB2CDFA4BE06Q38065305-616A5DBC-A5C4-46E7-BF9D-063500E89C9AQ38247168-05B649D0-D458-4D89-8942-AF01892B335FQ38674188-801EAC28-C06C-44C4-B878-DEFEFBAE18F1Q38897664-A0BA25FB-3397-4604-B435-3B25FD6BDE8BQ39009323-D910BEED-5007-4874-B439-94A18648E7A0Q39116877-FDEB89C9-6924-4FD4-8C26-A4E496745B57Q39185604-309192DE-ED61-4DFA-98DD-B8956DEF3089Q39512205-C8E53635-5CAA-4E17-97B7-3437BBC0FEDBQ39666504-A2BB835F-CFC9-46BE-BD70-6E6179A08005Q39685958-1D2B9152-E46F-45A9-9056-144D382362C7Q41583227-C5BD0F28-8550-445C-84C6-5768DFE5AAC2Q41876189-97CD66DF-68AF-49A9-AF0C-1CA373F9D991Q42566009-4574A33B-6498-49D8-A1D7-6FA1BAFB2FCCQ44027685-28A2484D-3E4A-431E-A894-19B724191561Q45764116-2718DF40-F189-487F-9411-8DA4A86F8C5EQ45960821-64F3DC60-4433-4B48-9F89-E8B960AA130EQ50450550-332D0134-70D8-47CD-B0DC-C25846F68AD1Q50958336-EEB301AD-0C80-43A2-9D15-AF823E4F7234
P2860
MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@en
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@nl
type
label
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@en
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@nl
prefLabel
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@en
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@nl
P2093
P356
P1476
MDM2 antagonist nutlin plus pr ...... rgistic anti-myeloma activity.
@en
P2093
Donald R Branch
Donna Reece
Hong Chang
Jennifer Jayakar
Manujendra N Saha
P304
P356
10.4161/CBT.9.11.11882
P577
2010-06-27T00:00:00Z